Secs 27/04/26 (SD21)

Pivot Calcs: SPX Pivot 7527---R1 7547---S1 7491---SPY Pivot 751---R1 753---S1 748----ES Pivot 7606---R1 7634---S1 7577----VIX Pivot 16.20---R1 16,64---S1 15.97---15 min Bull//Bear R/Line 17.42!------!!LOL!!

SEii Is Going Nuclear ☢️ With News.. Stay Tuned for life changing news$$$$

IMHO, one major event explicitly impacting the timeline of f2 relisting; IT IS NOT IN THE TOP TEN PRIORITIES, MAYBE NOT TOP 100. And, events all take precedence.

Translating the OLED Playbook to EOP
Reliability Challenge Modern OLED Solution Electro-Optic Polymer Equivalent
Moisture/Oxygen Ingress (Damp Heat) Dyadic Thin-Film Encapsulation (TFE / ALD) Atomic layer deposition (ALD) directly over the EOP slot
waveguide; passes 85/85 dam

It is unfortunate news that Halozyme eventually gave up the mdase patent.

https://www.thebionews.net/news/articleView.html?idxno=25562

Keep lying to yourself, we all know your looking for em cheapies.. The pedlar short flippers are out of ammo.. Your out of luck, got to slap the ask

Smart investors would take advantage of sharp price drops and scoop up cheap shares manically. To get Jack, you got to be nimble...nary tremble. Frick stay?

IMO, Australia and similarly situated oil consumers should treat this 60-day opening as temporary and they ought to buy and ship as much oil as they can gett their hands on in the next 60 days. These types of oil importers should be willing to pay top Dollar to obtain as much oil as they can handle

FNMA & FMCC Stock prices targets:
- 1st Target: $9, met 2026
- 2nd Target: $12, met 2026
- 3rd Target: $16, met 2026
- 4th Target: $20, met 2026
-5th Target: $30, met 2027
- 6th Target: $50, met 2027
- 7th Target: $70, met 2027
- 8th Target: $1

I wondered when you would resort to personal attacks.

Your arguments are weak and do not stand up to scrutiny.
So time to switch to plan B, attack the poster.

No I don't and neither do you. That is not the issue. NICE may not decide that the cost that NWBO is willing to accept is worth the result.

That is an unknown. If NICE looks at the data and decides that the survival benefit is not worth the cost then the treatment will not be reimbur

They could lease any of that cat-claw, cholla plagued land in the area....and it would all have the same mineral value. Zero.

Now past midway in June....where's Schappert's report?

ASX currently up 33% , ^.05 @ .20

You must keep averaging down every year and plan for some tax loss selling each year too. Gary is an expert at that.

Clearly not as you wouldn't understand a shady OTC biotech penny stock with little chance of success. You clearly have too much money tied up in this and seem to only respond with personal attacks. Not pretty, hope it's not your retirement money.

the acquisition NBRI has announced

What acquisition? Bendito? You actually think that happened? C'mon man......

Evidently you won't, and you can't deal with it and make personal attacks. Sorry, you evidently have too much money tied up in a shady OTC biotech stock that has little chance of going anywhere. Pretty defensive.

We are looking forward to your record breaking 100X miss this year. Only .08 more to go. Go Gary! ;)

https://www.linkedin.com/posts/hoganlovells_congratulations-to-our-longtime-client-delfin-activity-7472311054522359810-5wmR?utm_source=share&utm_medium=member_ios&rcm=ACoAACDR6B0BMOMVMFAaO8s015TkhTQ8bXv4VuQ

Number 1 and 2 of that also

Key Takeaway- Co-optimization with foundries for slots, slabs, rails, doping, and other fabrication specific
parameters is underway for 400Gb/s performance in EO polymer-based SOH modulators for
both O- and C-band
Lightwave Logic EO Polymer, Processes, and Designs are Ready

Just for the heck of it I took a look at Apple. Adjusted for splits the lowest it ever sold for was below $.04. If you invested in Apple at $.04 the way some of us have in NWBO at $.50 down to less than $.20, would you need anything else if NWBO has the sort of success that Apple has.

I wonder if your post is actionable for SLANDER


.

At least we know that UK decision is unlikely before July 3. And that they are still trying to justify the data by rallying the neuro oncology community. Not a good optic, particularly 30 months post submission if they are having to do that. Best case scenario is a conditional approval and no NICE r